Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Int J Toxicol ; 39(3): 241-247, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32308077

RESUMEN

Mesalazine is widely used in the management of inflammatory bowel disease. Previous studies reported that mesalazine-induced cardiotoxicity is a rare, potentially fatal complication. Mitochondria play an important role in myocardial tissue homeostasis. Deterioration in mitochondrial function will eventually lead to cardiomyocyte death and consequently cardiovascular dysfunction. The aim of the current study was to investigate the effects of mesalazine on rat heart mitochondria. Rat heart mitochondria were isolated by mechanical lysis and differential centrifugation. Parameters of mitochondrial toxicity including succinate dehydrogenase (SDH) activity, reactive oxygen species (ROS) formation, mitochondrial membrane potential (MMP) collapse, mitochondrial swelling, and cytochrome c release were evaluated. Results revealed that mesalazine induced a concentration- and time-dependent rise in mitochondrial ROS formation, inhibition of SDH, MMP collapse, mitochondrial swelling, and cytochrome c release in rat heart mitochondria. These results indicate that the cardiotoxic effects of mesalazine are most likely associated with mitochondrial dysfunction and ROS formation, which finally ends in cytochrome c release signaling and induction of apoptosis.


Asunto(s)
Antiinflamatorios no Esteroideos/toxicidad , Cardiotoxinas/toxicidad , Mesalamina/toxicidad , Mitocondrias Cardíacas/efectos de los fármacos , Animales , Cardiotoxicidad/etiología , Cardiotoxicidad/metabolismo , Cardiotoxicidad/fisiopatología , Citocromos c/metabolismo , Masculino , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Mitocondrias Cardíacas/metabolismo , Mitocondrias Cardíacas/fisiología , Estrés Oxidativo/efectos de los fármacos , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo
2.
Pharmazie ; 69(9): 676-9, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25272938

RESUMEN

We investigated whether nano-sized polystyrene particles affect drug-induced toxicity. The particles, which are widely used industrially, had diameters of 50 (NPP50), 200 (NPP200) or 1000 (NPP1000) nm. The toxic chemicals tested were acetaminophen (APAP), 5-aminosalicylic acid (5-ASA), tetracycline (TC), and sodium valproate (VPA). All treatments in the absence of the nanoparticles were non-lethal and did not result in severe toxicity. However, when mice were injected with APAP, 5-ASA or TC together with polystyrene particles, synergistic, enhanced toxicity was observed in mice injected with NPP50. These synergic effects were not observed in mice co-injected with NPP200 or NPP1000. On the other hand, co-administration of VPA and NPP50, NPP200 or NPP1000 did not elevate toxicity. The results show that NPP50 differs in hepatotoxicity depending on the drug co-administered. These findings suggest that further evaluation of the interactions between polystyrene nanoparticles and drugs is a critical prerequisite to the pharmaceutical application of nanotechnology.


Asunto(s)
Acetaminofén/toxicidad , Analgésicos no Narcóticos/toxicidad , Antibacterianos/toxicidad , Antiinflamatorios no Esteroideos/toxicidad , Mesalamina/toxicidad , Nanopartículas/toxicidad , Poliestirenos/toxicidad , Tetraciclina/toxicidad , Alanina Transaminasa/sangre , Animales , Aspartato Aminotransferasas/sangre , Nitrógeno de la Urea Sanguínea , Masculino , Ratones , Ratones Endogámicos BALB C , Tamaño de la Partícula
3.
Pharmazie ; 66(4): 282-6, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21612156

RESUMEN

Exposure to nano-sized particles is increasing because they are used in a wide variety of industrial products, cosmetics, and pharmaceuticals. Some animal studies indicate that such nanomaterials may have some toxicity, but their synergistic actions on the adverse effects of drugs are not well understood. In this study, we investigated whether 70-nm silica particles (nSP70), which are widely used in cosmetics and drug delivery, affect the toxicity of a drug for inflammatory bowel disease (5-aminosalicylic acid), an antibiotic drug (tetracycline), an antidepressant drug (trazodone), and an antipyretic drug (acetaminophen) in mice. Co-administration of nSP70 with trazodone did not increase a biochemical marker of liver injury. In contrast, co-administration increased the hepatotoxicity of the other drugs. Co-administration of nSP70 and tetracycline was lethal. These findings indicate that evaluation of synergistic adverse effects is important for the application of nano-sized materials.


Asunto(s)
Acetaminofén/toxicidad , Analgésicos no Narcóticos/toxicidad , Antibacterianos/toxicidad , Antiinflamatorios no Esteroideos/toxicidad , Mesalamina/toxicidad , Inhibidores Selectivos de la Recaptación de Serotonina/toxicidad , Dióxido de Silicio/química , Tetraciclina/toxicidad , Trazodona/toxicidad , Acetaminofén/química , Alanina Transaminasa/sangre , Analgésicos no Narcóticos/química , Animales , Antibacterianos/química , Antiinflamatorios no Esteroideos/química , Aspartato Aminotransferasas/sangre , Nitrógeno de la Urea Sanguínea , Inyecciones Intraperitoneales , Masculino , Mesalamina/química , Ratones , Ratones Endogámicos BALB C , Nanopartículas , Inhibidores Selectivos de la Recaptación de Serotonina/química , Tetraciclina/química , Trazodona/química
4.
Naunyn Schmiedebergs Arch Pharmacol ; 394(11): 2233-2244, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34410453

RESUMEN

Skin fibrosis is a complex biological remodeling process occurring in disease like systemic sclerosis, morphea, or eosinophilic fasciitis. Since the knowledge about the underlying pathomechanisms is still incomplete, there is currently no therapy, which prevents or reverses skin fibrosis sufficiently. The present study investigates the role of polo-like kinase 2 (PLK2) and the pro-fibrotic cytokine osteopontin (OPN) in the pathogenesis of cutaneous fibrosis and demonstrates the antifibrotic effects of systemic mesalazine treatment in vivo. Isolated primary dermal fibroblasts of PLK2 wild-type (WT) and knockout (KO) mice were characterized in vitro. Skin thickness and histoarchitecture were studied in paraffin-embedded skin sections. The effects of mesalazine treatment were examined in isolated fibroblasts and PLK2 KO mice, which were fed 100 µg/g mesalazine for 6 months via the drinking water. Compared to WT, PLK2 KO fibroblasts displayed higher spontaneous myofibroblast differentiation, reduced proliferation rates, and overexpression of the fibrotic cytokine OPN. In vitro, 72 h of treatment with 10 mmol/L mesalazine induced phenotype conversion in PLK2 KO fibroblasts and attenuated OPN expression by inhibiting ERK1/2. In vivo, dermal myofibroblast differentiation, collagen accumulation, and skin thickening were prevented by mesalazine in PLK2 KO. Plasma creatinine levels indicated good tolerability of systemic long-term mesalazine treatment. The current study reveals a spontaneous fibrotic skin phenotype and ERK1/2-dependent OPN overexpression in PLK2 KO mice. We provide experimental evidence for the antifibrotic effectiveness of systemic mesalazine treatment to prevent fibrosis of the skin, suggesting further investigation in experimental and clinical settings.


Asunto(s)
Fibroblastos/efectos de los fármacos , Mesalamina/farmacología , Proteínas Serina-Treonina Quinasas/genética , Piel/efectos de los fármacos , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/toxicidad , Diferenciación Celular/efectos de los fármacos , Colágeno/metabolismo , Creatinina/sangre , Modelos Animales de Enfermedad , Femenino , Fibroblastos/patología , Fibrosis/prevención & control , Masculino , Mesalamina/administración & dosificación , Mesalamina/toxicidad , Ratones , Ratones Noqueados , Osteopontina/genética , Piel/patología
5.
Arch Pharm Res ; 31(6): 736-41, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18563355

RESUMEN

Anti-inflammatory effects of three potassium salts of N,N-disubstituted 4-aminoazobenzenesulfonic acids were investigated and compared to that of acetylsalicylic acid (ASA) in rats with adjuvant arthritis (AA). Prophylactic oral administration of all compounds in a dose of 150 mg/kg ameliorated AA symptoms in animals. The most pronounced anti-inflammatory activity at the end of the experiment showed compound 1 containing imino group: it significantly suppressed joint swelling by 48.2% in female and by 44.2% in male rats with AA. The development of polyarthritis after the treatment with this compound was the lowest in female (20%) and male (40%) rats (in control--100% of animals with polyarthritis). All derivatives, and especially compound 1, also improved the systemic parameters of disease such as blood indices and internal organs' weight, and showed no toxicity on the main organs such as liver and spleen.


Asunto(s)
Antiinflamatorios/farmacología , Artritis Experimental/prevención & control , Bencenosulfonatos/farmacología , Mesalamina/farmacología , Administración Oral , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/toxicidad , Artritis Experimental/inducido químicamente , Artritis Experimental/patología , Bencenosulfonatos/administración & dosificación , Bencenosulfonatos/toxicidad , Femenino , Adyuvante de Freund , Pruebas Hematológicas , Articulaciones/efectos de los fármacos , Articulaciones/patología , Masculino , Mesalamina/administración & dosificación , Mesalamina/toxicidad , Tamaño de los Órganos , Ratas , Ratas Endogámicas Lew
7.
Food Chem Toxicol ; 97: 150-158, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27587080

RESUMEN

Our previous study demonstrated that a combination of alternative medicine berberine and conventional 5-aminosalicylic acid (5-ASA) showed promise to be a novel therapeutic strategy for ulcerative colitis (UC). This present study aims to sketch the pre-clinical toxicity profile of this combination (1:10 dose ratio) on mice. In acute toxicity test, the determined median lethal dose (LD50) was 278.7 mg/kg berberine plus 2787 mg/kg 5-ASA. The results from subacute toxicity test demonstrated that no toxic signs of clinical symptoms, no significant changes in hematological or biochemical parameters were detected in mice treated with 14 + 140, 28 + 280 or 56 + 560 mg/kg of berberine plus 5-ASA treatment. Histological examinations revealed that accompanied with an increase in spleen weight, frequently recorded enlargement and white pulp hyperplasia of spleen were detected in mice when exposed to three doses of combination treatments. Further in vitro assessment suggested that the spleen toxicity was originated from berberine by its inhibition in cell viability and cell proliferation of lymphocytes. The results of this study indicate that the combination of berberine and 5-ASA shows a slight toxic effect on spleen, suggesting that this combination should be used with caution for patients.


Asunto(s)
Antiinflamatorios no Esteroideos/toxicidad , Berberina/toxicidad , Eritrocitos/patología , Linfocitos/patología , Mesalamina/toxicidad , Pruebas de Toxicidad/métodos , Administración Oral , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Berberina/administración & dosificación , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos , Eritrocitos/efectos de los fármacos , Femenino , Linfocitos/efectos de los fármacos , Masculino , Mesalamina/administración & dosificación , Ratones , Ratones Endogámicos ICR
9.
Arch Pharm Res ; 28(6): 637-47, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16042070

RESUMEN

This work includes the synthesis of 15 final compounds (6a-h and 7b-h) as prodrugs of 5-ASA in the form of the acid itself, esters and amides linked by an amide linkage through a spacer to the endocyclic ring N of nicotinamide. Also, 15 new intermediate compounds were prepared. The target compounds (6b, 6f, 7b, and 7e-h) revealed potent analgesic and anti-inflammatory activities in comparison to sulfasalazine and 5-ASA. In addition, ulcerogenicity, LD50, in vivo and in vitro metabolism of compound 7f were determined.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Mesalamina/química , Profármacos/farmacología , Salicilamidas/farmacología , Salicilatos/farmacología , Analgésicos/síntesis química , Analgésicos/farmacología , Analgésicos/toxicidad , Animales , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/toxicidad , Carragenina , Estabilidad de Medicamentos , Edema/prevención & control , Heces/química , Contenido Digestivo/microbiología , Concentración de Iones de Hidrógeno , Dosificación Letal Mediana , Espectroscopía de Resonancia Magnética , Masculino , Mesalamina/farmacología , Mesalamina/toxicidad , Ratones , Dolor/prevención & control , Profármacos/síntesis química , Profármacos/toxicidad , Ratas , Salicilamidas/síntesis química , Salicilamidas/toxicidad , Salicilatos/síntesis química , Salicilatos/toxicidad , Úlcera Gástrica/inducido químicamente , Streptococcus pyogenes/metabolismo , Relación Estructura-Actividad
10.
Int J Oncol ; 17(1): 173-9, 2000 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10853036

RESUMEN

Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin have been shown to suppress colon carcinogenesis and in some cases reduce the size of colorectal polyps. Balsalazide disodium (BSZ) is a colon-specific prodrug of the salicylate, 5-aminosalicylic acid. The aim of the present study was to test the chemopreventive activity of BSZ in two established animal models of colon tumorigenesis, azoxymethane-induced aberrant crypt formation in the rat and intestinal tumor formation in the B6-Min/+ mouse. Aberrant crypt foci (ACF) were induced in Fischer 344 rats via 2 subcutaneous injections of azoxymethane (20 mg/kg). BSZ was supplied in the drinking water for 8 weeks and ACF quantitated. B6-Min/+ mice were treated from 55 days of age for 90 days and intestinal tumors scored for number, size and location. BSZ treatment of AOM-injected rats reduced ACF formation in a dose-dependent manner by 60% with the greatest effect observed on ACF with 4 or more crypts. In B6-Min/+ mice a dose-dependent reduction of intestinal tumor number was observed which reached 80% in the distal small intestine and colon. A preliminary mechanistic study in cultured human colon cancer cells showed that both BSZ and 5-ASA inhibited colon cancer cell proliferation in vitro. However, 5-ASA but not BSZ produced changes consistent with the induction of apoptosis. BSZ produces a dose-dependent chemopreventive effect on colon carcinogenesis. A possible mechanism is consistent with the inhibition of cellular proliferation and the induction of apoptosis.


Asunto(s)
Ácidos Aminosalicílicos/farmacología , Antiulcerosos/farmacología , Anticarcinógenos/farmacología , Azoximetano/toxicidad , Neoplasias del Colon/prevención & control , Mucosa Intestinal/efectos de los fármacos , Neoplasias Intestinales/prevención & control , Ácidos Aminosalicílicos/toxicidad , Animales , División Celular/efectos de los fármacos , Neoplasias del Colon/inducido químicamente , Neoplasias del Colon/patología , Genes APC , Humanos , Indometacina/toxicidad , Mucosa Intestinal/patología , Neoplasias Intestinales/inducido químicamente , Neoplasias Intestinales/patología , Mesalamina/toxicidad , Ratones , Ratones Mutantes , Fenilhidrazinas , Profármacos/toxicidad , Ratas , Ratas Endogámicas F344 , Células Tumorales Cultivadas
11.
J Toxicol Sci ; 23 Suppl 3: 539-52, 1998 Jul.
Artículo en Japonés | MEDLINE | ID: mdl-9760411

RESUMEN

A two stage carcinogenesis promotion test using phenobarbital (PB) as a positive control was performed on mesalazine in rats (F344,male). Pathological and immunohistological examinations were performed to examine the cell damage and proliferation in the liver and kidneys. As the initiation treatment, groups 1,2,3 and 5 were administered 300 mg/kg diethylnitrosamine (DEN)dissolved in 0.9% physiological saline, and group 4 was administered 5 ml/kg 0.9% physiological saline once intraperitoneally. Then group 1 was orally administered a water solution (5 ml/kg) containing 0.5% CMC-Na, and groups 2,3 and 4 similar water solution but containing 150, 300 and 300 mg/kg mesalazine, respectively. Group 5 was administered 0.05% PB mixed in feed from weeks 2 to 8. Partial (2/3) hepatectomy was performed in all 5 groups at week 3 after DEN administration. NO clear differences between the groups were observed in general conditions, body weight or amount of food consumption. The number or area-size of hepatic GST-P positive altered cell foci revealed no significant differences between groups 1,2 and 3, but a significant increase in number and area-size was observed in group 5. No GST-P positive cell foci were detected in group 4. The number of altered cell foci (H.E. staining) in the DENgroups administered mesalazine was the same as that in group 1. Thus, mesalazine did not promote hepatocarcinogenesis in the present experimental system. Statistically insignificant appearances of basophilic and acidophilic changes were observed in the renal tubular epithelium and mineral deposits in the renal papillary region and cortical margin region. The PCNA labeling rate was significantly lower in group 4, corresponding with the histological finding showing no proliferation of the renal tubular epithelium. Judging from the above test results, mesalazine was likely to show neither a promotion effect on the initiation induced by DEN nor cell proliferative activity on the kidneys by administration for this experimental period.


Asunto(s)
Antiinflamatorios no Esteroideos/toxicidad , Hígado/efectos de los fármacos , Mesalamina/toxicidad , Administración Oral , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Peso Corporal/efectos de los fármacos , Pruebas de Carcinogenicidad/métodos , Ingestión de Alimentos/efectos de los fármacos , Riñón/efectos de los fármacos , Masculino , Mesalamina/administración & dosificación , Ratas , Ratas Endogámicas F344
13.
Hum Exp Toxicol ; 30(7): 772-6, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20670990

RESUMEN

Drugs containing 5-acetylsalicylic acid (5-ASA) have been commonly used for inflammatory bowel diseases for more than half a century, but no case about overdose of suppository form of mesalazine which was taken both orally and rectally has been reported in the related literature up to now. In the present case, a 20-year-old male patient who took 14.5 g of mesalazine rectally and orally for suicide purpose is discussed. He was an ulcerative colitis patient and depressed about his illness and routine life traffic. Although it was hard for him to take the suppository form orally because of its bad taste and structure, he took it with the help of water. In the patient's colonoscopy, diffuse hyperemia and edema extending from the anal channel to the proximal rectal mucosa and a 1.5 cm diameter ulcer expanding from anal channel through the rectum were identified. No pathology was found in the upper gastrointestinal endoscopy. Routine laboratory examination was performed and no abnormality was identified in the patient's total blood account, biochemical parameters and full-urine examination. In the control rectoscopy applied to the patient 15 days later, recovery of the ulcer was observed and he was discharged to be followed in the psychiatry clinic.


Asunto(s)
Antiinflamatorios no Esteroideos/toxicidad , Mesalamina/toxicidad , Intoxicación/etiología , Intento de Suicidio , Administración Oral , Administración Rectal , Antiulcerosos/uso terapéutico , Carbón Orgánico/administración & dosificación , Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/patología , Colonoscopía , Sobredosis de Droga , Fluidoterapia , Lavado Gástrico , Humanos , Masculino , Intoxicación/patología , Intoxicación/terapia , Sucralfato/uso terapéutico , Supositorios , Resultado del Tratamiento , Adulto Joven
14.
Toxicology ; 280(3): 71-6, 2011 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-21115095

RESUMEN

Mesalamine is the first line pharmacologic intervention for patients with ulcerative colitis, and recent epidemiologic studies have demonstrated a protective association between therapeutic use of the drug and colorectal carcinoma. However, the mechanism by which this protection is afforded has yet to be elucidated. Because copper is found at higher than normal concentrations in neoplastic cell nuclei and is known to interact with phenolic compounds to generate reactive oxygen species, we investigated whether the reaction of mesalamine/copper was able to induce oxidative DNA strand breaks in φX-174 RF I plasmid DNA, and the various components of the mechanism by which the reaction occurred. Plasmid DNA strand breaks were induced by pharmacologically relevant concentrations of mesalamine in the presence of a micromolar concentration of Cu(II), and damage was inhibited by bathocuproinedisulfonic acid (BCS) and catalase. Further, we showed that the reaction of copper with mesalamine consumed molecular oxygen, which was inhibited by BCS. Electron paramagnetic resonance spectral analysis of the reaction of copper/mesalamine indicated the presence of the hydroxyl radical, which was inhibited by both BCS and catalase. This study demonstrates for the first time that through a copper-redox cycling mechanism, the copper-mediated oxidation of mesalamine is a pro-oxidant interaction that generates hydroxyl radicals which may participate in oxidative DNA damage. These results demonstrate a potential mechanism of the anticancer effects of mesalamine in patients with ulcerative colitis.


Asunto(s)
Antineoplásicos/toxicidad , Cobre/toxicidad , Daño del ADN/efectos de los fármacos , Mesalamina/toxicidad , Estrés Oxidativo/efectos de los fármacos , Especies Reactivas de Oxígeno/toxicidad , Antineoplásicos/farmacocinética , Cobre/farmacocinética , Daño del ADN/fisiología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas/fisiología , Humanos , Mesalamina/farmacocinética , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo/fisiología , Especies Reactivas de Oxígeno/metabolismo
15.
Cell Biol Toxicol ; 13(6): 445-51, 1997 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9352122

RESUMEN

Nonsteroidal anti-inflammatory drugs can cause serious side-effects such as tubulo-interstitial nephritis. Mesalazine (5-ASA, 5-aminosalicylic acid) is used for the treatment of colitis ulcerosa, Crohn disease, and other diseases; it has been found to induce necrosis of both proximal convoluted tubules and renal papillaries. The comparative cytotoxicity of 3-, 4-, and 5-aminosalicylic acid, acetylsalicylic acid (AcSA), and the parent compound salicylic acid (SA) was investigated for the free acids and for their sodium salts. The interaction with endogenous glutathione (GSH) was also investigated. Four established cell lines were used: MDCK, LLC-PK1, NRK as renal cells, and HepG2 as hepatic cells. The free acid compounds were less toxic than their corresponding salts. Acidic 5-ASA was the most toxic of the three isomers in MDCK and LLC-PK1 cells, while NRK and HepG2 were more susceptible to acidic 3-ASA. Addition of NaOH modified the relative toxicity of 3-ASA and 5-ASA. The LLC-PK1 and HepG2 cells were more sensitive to the test chemicals as their salts than were the NRK and MDCK cells. SA and 5-ASA decreased the GSH content in renal cells and increased it in HepG2. GSH depletion with L-buthionine-(S,R)-sulfoximine enhanced the toxicity only for SA in NRK and for 5-ASA and AcSA in HepG2. No correlation between endogenous GSH and the susceptibility of MDCK and LLC-PK1 to the test compounds was observed. The results suggest that no typical nephrotoxic effect occurred. No explanation could be found for the tubulo-interstitial nephritis caused by 5-ASA therapy.


Asunto(s)
Ácido Aminosalicílico/toxicidad , Antiinflamatorios no Esteroideos/toxicidad , Aspirina/toxicidad , Mesalamina/toxicidad , Salicilatos/toxicidad , Animales , Aspirina/química , Línea Celular/efectos de los fármacos , Perros , Glutatión/análisis , Humanos , Túbulos Renales/efectos de los fármacos , Rojo Neutro , Ratas , Salicilatos/química , Ácido Salicílico , Relación Estructura-Actividad , Porcinos , Células Tumorales Cultivadas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda